title: Recombinant human decorin upregulates p57KIP² expression in HepG2 hepatoma cell lines.
abstract: Increasing the expression of cyclin-cyclin-dependent kinase inhibitors (cyclin-CDK) using small molecule inhibitors is a therapeutic strategy used to suppress cancer cell growth. Decorin (DCN), a functional component of the extracellular matrix, has been implicated in the suppression of cell proliferation by upregulating p21, a cyclin-CDK inhibitor. The purpose of this study was to examine the effect of recombinant decorin on the reactivation of p57KIP2, whose expression is silenced in hepatocellular carcinoma (HCC). Cell viability assay, cell cycle analysis, apoptosis assay and quantitative real time-PCR experiments were performed in three groups of HepG2 human cells: Uninfected HepG2 cells (control group), pcDNA3.1 vector-infected HepG2 cells (pcDNA3.1 group) and pcDNA3.1-DCN-infected HepG2 cells (pcDNA3.1‑DCN group). Our results revealed that recombinant human decorin inhibited cell proliferation, induced G0/G1 phase arrest and induced apoptosis by increasing the expression of caspase-3 in the pcDNA3.1-DCN group. The expression of p57KIP2 mRNA in the pcDNA3.1-DCN group was higher than in the pcDNA3.1 and control groups (P<0.05); however, there was no statistically significant difference between the control and pcDNA3.1 groups (P>0.05). In conclusion, recombinant human decorin reactivated p57KIP2 expression in HepG2 cells. As the expression level of p57KIP2 is downregulated in HCC, our finding may serve as a basis for the therapy and prognosis of HCC, although further studies are required.
authors.affiliation: Central Laboratory, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China.
authors.forename: Abdu Selim
authors.initials: AS
authors.lastname: Hamid
authors.forename: Jinran
authors.initials: J
authors.lastname: Li
authors.forename: Yali
authors.initials: Y
authors.lastname: Wang
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Wu
authors.forename: Hassan Abdellah Ahmed
authors.initials: HA
authors.lastname: Ali
authors.forename: Zhenwu
authors.initials: Z
authors.lastname: Du
authors.forename: Lihua
authors.initials: L
authors.lastname: Bo
authors.forename: Yucheng
authors.initials: Y
authors.lastname: Zhang
authors.forename: Guizhen
authors.initials: G
authors.lastname: Zhang
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D050761:Cyclin-Dependent Kinase Inhibitor p57 / Q000235:genetics* / Q000378:metabolism; D058575:Decorin / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics* / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology*
chemical_list: D050761:Cyclin-Dependent Kinase Inhibitor p57; D058575:Decorin; D011994:Recombinant Proteins